Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

This study tests a combination of two drugs — osimertinib (a targeted therapy for EGFR-mutant lung cancer) and tegavivint (a drug that blocks a cancer cell survival pathway called Wnt/beta-catenin) — as a first-line treatment for people with metastatic non-small cell lung cancer carrying an EGFR mutation. Adding tegavivint may help delay resistance to osimertinib. **You may be eligible if...** - You are 18 or older with confirmed metastatic non-small cell lung cancer (NSCLC) - Your tumor has a common EGFR mutation (exon 19 deletion or L858R) confirmed by tumor biopsy - You have not yet received any treatment for metastatic NSCLC - Your organ function (blood, liver, kidneys) is adequate **You may NOT be eligible if...** - You do not have an EGFR mutation confirmed by tumor tissue testing - You have previously received osimertinib or another EGFR-targeted drug - You have untreated or unstable brain metastases - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.